Business

Announcement on Voluntary Disclosure of Completing Enrollment of the First Subject in Phase III Clinical Trial of BL-M07D1 (HER2 ADC) for Injection for Postoperative Adjuvant Therapy of HER2-Positive Breast Cancer with Residual Invasive Carcinoma after Neoadjuvant Therapy

Announcement on Voluntary Disclosure of Completing Enrollment of the First Subject in Phase III Clinical Trial of BL-M07D1 (HER2 ADC) for Injection for Postoperative Adjuvant Therapy of HER2-Positive Breast Cancer with Residual Invasive Carcinoma after Neoadjuvant Therapy

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AJune 23, 20253/news/announcement-on-voluntary-disclosure-of-completing-enrollment-of-the-first-subject-in-phase-iii-clinical-trial-of-bl-m07d1-her2-adc-for-injection-for-postoperative-adjuvant-therapy-of-her2-positive-breast-cancer-with-residual-invasive-carcinoma-after-neoadjuvant-therapy
Announcement on Voluntary Disclosure of Completing Enrollment of the First Subject in Phase III Clinical Trial of BL-M07D1 (HER2 ADC) for Injection for Postoperative Adjuvant Therapy of HER2-Positive Breast Cancer with Residual Invasive Carcinoma after Neoadjuvant Therapy

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Completing Enrollment of the First Subject in Phase III Clinical Trial of BL-M07D1 (HER2 ADC) for Injection for Postoperative Adjuvant Therapy of HER2-Positive Breast Cancer with Residual Invasive Carcinoma after Neoadjuvant TherapyThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A